Protracted Radiation Exposure Linked to Hematologic Cancer Mortality
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 24, 2024 -- Protracted low-dose exposure to ionizing radiation among radiation-monitored workers is associated with mortality due to some hematologic malignancies, according to a study published online in the October issue of The Lancet Hematology.
Klervi Leuraud, Ph.D., from the Institut de Radioprotection et de Sûreté Nucléaire in Fontenay-aux-Roses, France, and colleagues examined the associations between radiation dose and mortality due to hematologic malignancies in a cohort of 309,932 radiation-monitored workers employed for at least one year by nuclear facilities in France, the United Kingdom, and the United States.
The researchers found that a linear model described the association between cumulative dose to red bone marrow, lagged two years, and leukemia (excluding chronic lymphocytic leukemia; excess relative rate per Gy, 2.68), which was not modified by neutron exposure, internal contamination monitoring status, or period of hire. For chronic myeloid leukemia and myelodysplastic syndromes alone or combined with acute myeloid leukemia, positive associations were also seen (excess relative rates per Gy, 9.57, 3.19, and 1.55, respectively). For acute lymphoblastic leukemia or chronic lymphocytic leukemia, no significant association was seen. There was a positive association between radiation dose and multiple myeloma (excess relative rate per Gy, 1.62); minimal evidence of association was seen between radiation dose and non-Hodgkin or Hodgkin lymphoma mortality.
"Studies of people exposed to low doses of radiation add to our understanding of radiation risks at the exposure levels of contemporary concern, and thus can inform radiation protection efforts," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-25 06:00
Read more
- Diadem Unveils Novel Findings on Early Alzheimer's Disease Detection Using p53-Specific Antibody at CTAD 2024
- FDA Approves Orlynvah (sulopenem etzadroxil and probenecid) for the Treatment of Uncomplicated Urinary Tract Infections
- Get With The Guidelines-Stroke Participation Has Improved Stroke Care
- AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
- Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM
- Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions